Trial Profile
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of CNTO 1959 (Guselkumab) in the Treatment of Subjects With Moderate to Severe Plaque-type Psoriasis
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Guselkumab (Primary)
- Indications Plaque psoriasis
- Focus Therapeutic Use
- Sponsors Janssen Pharmaceuticals
- 21 Feb 2019 Status changed from active, no longer recruiting to completed.
- 03 Oct 2018 Planned End Date changed from 21 Sep 2018 to 28 Feb 2019.
- 20 Apr 2018 Status changed from recruiting to active, no longer recruiting.